



## Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

September 27, 2021

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- [Verve Therapeutics](#), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief medical officer, will participate in a fireside chat during the Chardan Virtual 5<sup>th</sup> Annual Genetics Medicines Conference on Monday, October 4, 2021 at 11:00 a.m. ET. Dr. Kathiresan will also participate in a panel titled, "Genetic Medicines: The Ongoing Emergence of the Heart as a Target Tissue Panel" on Monday, October 4, 2021 at 3:00 p.m. ET.

A live webcast of the fireside chat will be available in the investor section of the company's website at [www.vervetx.com](http://www.vervetx.com). The webcast will be archived for 60 days following the presentation.

### About Verve Therapeutics

Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve's lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient's risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit [www.VerveTx.com](http://www.VerveTx.com).

### Media Contact

Gina Nugent, 617-460-3579  
Ten Bridge Communications  
[gina@tenbridgecommunications.com](mailto:gina@tenbridgecommunications.com)

### Investor Contact

Monique Allaire  
THRUST Strategic Communications  
[monique@thrustsc.com](mailto:monique@thrustsc.com)